Drugs could mimic gut bacteria benefits to treat diabetesIt may be possible to design drugs that mimic the positive health benefits of gut bacteria to treat Share XDrugs could mimic gut bacteria benefits to treat diabeteshttps://pharmaphorum.com/news/drugs-gut-bacteria-diabetes/
Alnylam to file gene-silencing porphyria drugAlnylam is to file its givosiran with regulators to treat a form of the blood disease porphyria, applying Share XAlnylam to file gene-silencing porphyria drughttps://pharmaphorum.com/news/alnylam-to-file-gene-silencing-porphyria-drug/
J&J’s Invokana reduces risk of renal failure in high-risk diabetes patientsJohnson & Johnson’s Janssen pharma unit has announced new results showing that its Invokana diabetes medicine is the Share XJ&J’s Invokana reduces risk of renal failure in high-risk diabetes patientshttps://pharmaphorum.com/news/jjs-invokana-reduces-risk-of-renal-failure-in-high-risk-diabetes-patients/
Gilead and Novo Nordisk collaborate for NASH trialGilead and Novo Nordisk have announced that they will collaborate on a clinical trial in nonalcoholic steatohepatitis (NASH) Share XGilead and Novo Nordisk collaborate for NASH trialhttps://pharmaphorum.com/news/gilead-and-novo-nordisk-collaborate-for-nash-trial/
Wave slips behind in Huntington’s disease antisense raceSlower-than-expected recruitment in trials of two of Wave Life Sciences’ experimental therapies of Huntington’s disease will delay results, Share XWave slips behind in Huntington’s disease antisense racehttps://pharmaphorum.com/news/wave-huntingtons-disease-antisense-race/
Janssen announces first data centres for haematology networkJanssen has announced the first two data centres to join its HONEUR (Haematology Outcomes Network in Europe) collaborative Share XJanssen announces first data centres for haematology networkhttps://pharmaphorum.com/news/janssen-announces-first-data-centres-for-haematology-network/
Trial sets up 2020 filing for Poxel’s novel diabetes drugFrench biotech Poxel has positive phase 3 data for a new type of oral therapy for type 2 Share XTrial sets up 2020 filing for Poxel’s novel diabetes drughttps://pharmaphorum.com/news/trial-sets-up-2020-filing-for-poxels-novel-diabetes-drug/
Novartis completes spin-out of Alcon eye unitNovartis’ long-awaited separation from its eye care division Alcon completed on schedule today, allowing it to focus its Share XNovartis completes spin-out of Alcon eye unithttps://pharmaphorum.com/news/novartis-completes-spin-out-of-alcon-eye-unit/
Regeneron and Alnylam announce $1bn collaborationRegeneron has signed a collaboration deal potentially worth $1 billion with RNAi experts Alnylam Pharmaceuticals, to develop and Share XRegeneron and Alnylam announce $1bn collaborationhttps://pharmaphorum.com/news/regeneron-and-alnylam-announce-1bn-collaboration/
Ocugen, Histogenics merge to form eye disease specialistUS biotechs Ocugen and Histogenics have announced plans to merge, creating a specialist in drugs and gene therapies Share XOcugen, Histogenics merge to form eye disease specialisthttps://pharmaphorum.com/news/ocugen-histogenics-merge-to-form-eye-disease-specialist/
Sanofi and Alnylam conclude research phase of RNAi allianceSanofi and Alnylam have agreed to conclude the research and option phase of their 2014 RNAi therapeutics alliance Share XSanofi and Alnylam conclude research phase of RNAi alliancehttps://pharmaphorum.com/news/sanofi-and-alnylam-conclude-research-phase-of-rnai-alliance/
Gilead files Truvada follow-up Descovy for PrEPGilead Sciences has filed Descovy, its successor to HIV pre-exposure prophylaxis (PrEP) therapy Truvada, in the US, spending Share XGilead files Truvada follow-up Descovy for PrEPhttps://pharmaphorum.com/news/gilead-files-truvada-follow-up-descovy-for-prep/
Real-world data unlocks Ibrance ok in male breast cancerThe FDA has expanded the use of Pfizer’s Ibrance to include use in breast cancer in men based Share XReal-world data unlocks Ibrance ok in male breast cancerhttps://pharmaphorum.com/news/real-world-data-unlocks-ibrance-ok-in-male-breast-cancer/
GSK adds to COPD pipeline as Exscientia deal bears fruitAI drug research firm Exscientia has delivered the first candidate molecule to its partner GlaxoSmithKline following an R&D Share XGSK adds to COPD pipeline as Exscientia deal bears fruithttps://pharmaphorum.com/about-pharmaphorum/gsk-adds-to-copd-pipeline-as-exscientia-deal-bears-fruit/
Roche insists Spark deal is still on, despite lacklustre take-upShareholders in Spark Therapeutics haven’t been queueing up to take advantage of Roche’s $114.50-per-share offer, forcing an extension Share XRoche insists Spark deal is still on, despite lacklustre take-uphttps://pharmaphorum.com/news/roche-insists-spark-deal-still-on-despite-lacklustre-take-up/
AZ’s Fasenra also works in rare organ damage diseasesAstraZeneca’s asthma drug Fasenra also works in a group of rare diseases that can lead to potentially fatal Share XAZ’s Fasenra also works in rare organ damage diseaseshttps://pharmaphorum.com/news/azs-fasenra-also-works-in-rare-organ-damage-diseases/
Merck’s oral MS drug finally gets FDA okayMerck KGaA has finally claimed an FDA approval for its oral multiple sclerosis therapy Mavenclad, eight years after Share XMerck’s oral MS drug finally gets FDA okayhttps://pharmaphorum.com/news/mercks-oral-ms-drug-finally-gets-fda-okay/
Novartis buys NASH biotech IFM Tre in potential $1.575 bn dealNovartis is to buy US biotech IFM Tre in a deal worth up to $1.575 billion, adding a Share XNovartis buys NASH biotech IFM Tre in potential $1.575 bn dealhttps://pharmaphorum.com/news/novartis-buys-nash-biotech-ifm-tre-in-potential-1-575-bn-deal/
